Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Portuguese
  • Polish

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Phage therapy: a new way to restore the effectiveness of chemotherapy
  • Our publications
    • News
    • HCP Magazine
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • Diagnosis tools
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
General Medicine

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Phage therapy: a new way to restore the effectiveness of chemotherapy
Gastroenterology

Phage therapy: a new way to restore the effectiveness of chemotherapy

Cancer
Gastroenterology Oncology

A Chinese research team has recently identified a bacterium in the gut microbiota that may be involved in chemotherapy resistance in patients with colorectal cancer. They have also identified a phage capable of specifically targeting this bacterium and restoring tumor sensitivity to treatment.

Gastroenterology
Gynecology
Pediatrics
General Medicine
  • Our publications
    • News
    • HCP Magazine
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • Diagnosis tools
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

About this article

Created 07 October 2025
Updated 14 October 2025

Will phages (viruses that target bacteria) soon be part of the therapeutic arsenal for fighting colorectal cancer (CRC)? So suggests a fascinating study published in the journal Cell Host & Microbe. 1

According to the authors, a gut bacterium found in abundance in those who fail to respond to treatment may be responsible for resistance to chemotherapy. Eradicating this bacterium with phages may make it possible to restore the sensitivity of cancer cells to treatment and thus improve patient survival.

To show this, the researchers went through several stages. First, based on the analysis of the microbiota of two independent cohorts of patients (a total of 106 patients, 34 of whom did not respond to treatment), they noticed that the abundance of the bacterium Bacteroides fragilis was significantly higher in non-responders, and that this abundance was correlated with a poorer prognosis.

1.9 million The number of new cases of colorectal cancer worldwide in 2020. ²

930,000 The number of deaths related to colorectal cancer in 2020. ²

A gut bacterium that worsens prognosis

The scientists asked whether B. fragilis was responsible for chemoresistance. To test their hypothesis, they cultured human cancer cells in the presence of B. fragilis and then with two chemotherapy drugs, 5-fluorouracil (5-FU) and oxaliplatin (OXA).

The results indicated that B. fragilis does indeed reduce the sensitivity of cancer cells to chemotherapy, in particular by suppressing chemotherapy-induced apoptosis. These results were confirmed in vivo in the same experiment on mouse models of CRC, with a greater number of tumors present in mice exposed to B. fragilis than in those not exposed, following treatment with 5-FU and OXA.

An RNA analysis of the cells co-cultured with or without B. fragilis and then treated with 5-FU and OXA showed that B. fragilis upregulates the Notch1 metabolic pathway that appears to underlie the chemoresistance of CRC cells.

Photo: Fecal microbiota: a biomarker for colorectal cancer and its progression 21.08.2025 Fecal microbiota: a biomarker for colorectal cancer and its progression Read more

Fragilis but formidable

The researchers then asked what interactions between the bacteria and cancer cells activated the Notch1 pathway. Using scanning electron microscopy of cells in vitro and in vivo, they observed that B. fragilis did indeed adhere to cancer cells.

According to the authors, on the surface of the bacteria there is a membrane lipoprotein from the SusD/RagB family that is capable of binding specifically to Notch1 receptors on cancer cells. This binding activates the Notch1 signaling pathway and induces the “epithelial-to-mesenchymal transition”, which corresponds to the first stage of cancer cell dissemination (metastases).
 

3rd most common type of cancer. ²

2nd most common cause of cancer-related death. ²

People over 50 are the most affected. ²

Phages to the rescue

To cap off the study, the researchers identified a phage called VA7 that is capable of specifically eliminating B. fragilis safely and effectively. They administered the VA7 phage to CRC mice that had become chemoresistant following exposure to B. fragilis and found that it completely reversed the induced chemoresistance.

This study is particularly interesting because it shows that:

  • An abundance of B. fragilis in the microbiota of CRC patients could serve as a non-invasive biomarker to predict the effectiveness of chemotherapy. 
  • Combining chemotherapy with VA7 phages in patients with an abundance of B. fragilis could improve clinical response without side effects.
     

To be continued...

B. fragilis is not the only bacterium that influences the prognosis of colon cancer

According to French researchers, colibactin-producing Escherichia coli (a genotoxic and protumor substance) is also present in abundance in certain colorectal cancers, particularly right-sided colon cancer. 3 This bacterium makes cancer cells less visible to the antitumor immune system and less sensitive to the action of chemotherapy. In 2019, a Chinese study 4 showed that Fusobacterium nucleatum also reduced the effectiveness of 5-fluorouracil.

The microbial-metabolic nexus in colon cancer

Learn more
Sources

1. Ding X, Ting NL, Wong CC, et al. Bacteroides fragilis promotes chemoresistance in colorectal cancer, and its elimination by phage VA7 restores chemosensitivity. Cell Host Microbe. 2025 Jun 11;33(6):941-956.e10.

2. https://www.who.int/fr/news-room/fact-sheets/detail/colorectal-cancer

3. de Oliveira Alves N, Dalmasso G, Nikitina D, et al. The colibactin-producing Escherichia coli alters the tumor microenvironment to immunosuppressive lipid overload facilitating colorectal cancer progression and chemoresistance. Gut Microbes. 2024 Jan-Dec;16(1):2320291.

4. https://www.biocodexmicrobiotainstitute.com/fr/pro/cancer-colorectal-une-bacterie-au-coeur-de-la-chimioresistance

Tags
Gut microbiota Gastroenterology Colorectal cancer Cancer Gastrointestinal system Functional gastrointestinal disorders Microbiome Flora

    See also

    From the mouth to the colon: tracing the route of Fusobacterium
    Serum metabolites associated with gut microbiota: improved diagnosis for colorectal cancers?
    Created 07 October 2025
    Updated 14 October 2025

    About this article

    To know more about this topic.

    Main topic

    Cancer

    Medical practice

    Gastroenterology Oncology

    Content type

    News
    Gastroenterology

    Probiotics: what exactly are we talking about?

    From the Latin pro and Greek bios meaning “for life”, the term “probiotic” was suggested over 60 years ago,...

    Find out more

    Association between fungal dysbiosis and environment

    The fungal portion of the gut microbiota (or mycobiota) has been much less studied than the bacterial porti...

    Find out more

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irritable Bo...

    Find out more

    How do you choose a probiotic for your patient?

    Faced with a plethora of products on the market, it's not always easy for health professionals to suggest a...

    Find out more

    The Janus face of Antibiotics: Life Savers and Microbiota Disruptors

    A page turns: with the advent of antibiotics in the 20th century, this type of therapy, despite its undoubt...

    Find out more

    Fecal transplantation - ready for prime time?

    Congress review By Pr. Danny De Looze Department of Gastroenterology University Hospital Gent, Belgium ...

    Find out more

    Focus on antibiotic associated diarrhea (AAD)

    Find out more

    Dampening gastrointestinal inflammation through nutrition

    by Dr Genelle Healey

    Find out more

    Continue reading

    News
    Parkinson : le microbiote intestinal, chef d’orchestre des mécanismes pathogéniques ?
    27.02.2023

    Does the gut microbiota orchestrate pathogenic mechanisms in Parkinson’s disease?

    Read the article
    25.08.2025

    Anorexia nervosa: is the unconscious mind influenced by the gut microbiota?

    Read the article
    25.08.2025

    Specific microbial species correlate with amyloid and tau pathology in Alzheimer’s disease

    Read the article
    Photo: Fecal microbiota: a biomarker for colorectal cancer and its progression
    21.08.2025

    Fecal microbiota: a biomarker for colorectal cancer and its progression

    Read the article
    Everything you need to know about Microbiota & Dysbiosis
    27.07.2022

    Everything you need to know about Dysbiosis

    Read the article
    Everything you need to know about Microbiota & Immunity
    15.09.2022

    Everything you need to know about Microbiota & Immunity

    Read the article
    16.07.2025

    Diabetes prevention: is Candida a good candidate?

    Read the article
    11.07.2025

    Cancer: microbiota involved in the abscopal effect

    Read the article
    • Our publications
      • News
      • HCP Magazine
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • Diagnosis tools
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine
    • English
    • Français
    • Español
    • Portuguese
    • Polish

    Browse the site

    • Our publications
      • News
      • HCP Magazine
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • Diagnosis tools
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "HCP Magazine" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    07.10.2025

    Phage therapy: a new way to restore the effectiveness of chemotherapy

    Read the article
    23.09.2025

    Can glycans and vaginal microbiota play a role in the fight against preterm birth?

    Read the article
    23.09.2025

    ART and embryo transfer: are lactobacilli the key to success?

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "HCP Magazine" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • HCP Magazine
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • Diagnosis tools
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    © 2025 Biocodex. All rights reserved.

    • Legal notice
    • GTU
    • Data protection policy
    • Sitemap
    • Cookies settings
    • Digital accessibility : partially compliant
    Biocodex logo